Targeted delivery conjugation platform — GalNAc, folate, and receptor-specific ligand strategies for siRNA, ASO, SSO, and advanced therapeutic oligos.
Tissue and receptor-targeted oligonucleotide conjugation is a critical strategy for improving therapeutic delivery by directing oligonucleotides to specific cells, tissues, or receptor systems. Rather than relying only on passive distribution, ligand-directed conjugation can improve uptake, reduce off-target exposure, and enhance pharmacological performance.
Bio-Synthesis supports targeted conjugation platforms that can be integrated with siRNA, antisense oligonucleotides (ASO), splice-switching oligonucleotides (SSO), and other advanced oligo formats. Our service focus includes Oligo-GalNAc conjugation for hepatocyte targeting, Oligo-Folate conjugation for folate receptor-directed applications, and custom receptor-targeting ligand conjugates built around receptor biology and delivery goals.
targeted oligo delivery platform
Receptor-aware oligonucleotide design with control over targeting ligand, linker architecture, and downstream delivery objective.
Ligands
Established targeting systems
Custom
Peptides and small molecules
Formats
Multiple oligo classes
Design
Linker and spacing options
GalNAc-conjugated oligonucleotides are widely used for hepatocyte-directed delivery through asialoglycoprotein receptor (ASGPR)-mediated uptake.
View Service Details →
Folate-conjugated oligonucleotides enable receptor-directed uptake in cells expressing folate receptors, especially in oncology and receptor biology workflows.
Custom receptor-targeting ligand conjugates support delivery through peptides, carbohydrates, small molecules, or other receptor-recognizing ligands matched to the target biology.
This summary table helps distinguish each targeting platform by receptor biology, tissue focus, and common development use.
A structured workflow from receptor selection to conjugation design and downstream delivery evaluation.
Workflow Diagram
Ligand-mediated uptake can increase delivery efficiency into receptor-positive target tissues and cell populations.
Directed uptake can help reduce distribution to non-target tissues and improve the therapeutic window.
Targeting ligands can be combined with different oligonucleotide classes, linkers, and backbone chemistries depending on program goals.
siRNA, antisense oligonucleotides, splice-switching oligonucleotides, and other therapeutic oligonucleotide formats can be adapted to ligand-mediated targeting strategies depending on chemistry and program goals.
GalNAc is widely used for hepatocyte-directed delivery because it binds the asialoglycoprotein receptor on liver cells and enables receptor-mediated uptake.
Folate conjugation is useful when targeting cells that express folate receptors, especially in oncology and receptor-mediated delivery studies.
Yes. Ligand-directed conjugates may use peptides, carbohydrates, small molecules, or other receptor-recognizing motifs depending on the delivery objective and receptor biology.
Contact
Share the oligonucleotide format, target tissue or receptor, preferred ligand or conjugation concept, linker requirements, and current development stage. We’ll help define a practical conjugation strategy and quoting path.
Tip: Include the oligo class, receptor target, ligand preference, and intended tissue to speed technical review.
Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.